Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Revenues Up Again; Earnings Also Improve in Q2

NEW YORK, July 21 (GenomeWeb News) - Invitrogen's revenues and earnings increased for the second quarter, the company reported today.


Revenues increased approximately 32 percent to $254 million, as compared to $192.4 million reported for the second quarter of 2003.


Invitrogen said that the revenue growth included a 19 percent increase in its BioDiscovery unit, due principally to its Molecular Probes acquisition. It also attributed a 53 percent increase in revenues for its BioProduction products to its acquisition of BioReliance and solid customer demand for its cell culture products.


Net income for the second quarter also increased, to $19.7 million, from $16.9 million for Q2 of 2003.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant, Science paper finds.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.